Amicogen Corrects Business Report: Understated Impairment Loss on Puriogen Increases Net Loss by KRW 7.6B

Amicogen corrects its 25th business report: Impairment loss on subsidiary Puriogen understated by KRW 7,645 million due to valuation model error.
Correction: Separate basis: Investments in subsidiaries and associates decreased by KRW 7,645M (from 49,211M to 41,565M), total equity decreased by KRW 7,645M (from 137,673M to 130,027M), net loss increased by KRW 7,645M (from 31,693M to 39,338M).
Separate debt ratio rose to 101.0% (from 95.4%), net debt ratio to 70.6% (from 66.7%). Consolidated debt ratio surged to 139.0% (from 113.3%), net debt ratio to 95.7% (from 50.5%).
During the period, divested stakes in subsidiaries (Amicogen China, Skinmed, AP, etc.) and merged with Beyond Cell.
No shareholder return activities (no share buybacks, dividends).
Consolidated revenue KRW 173.6B (+8.6% YoY), operating loss KRW 7.1B, net loss KRW 50.9B.